Concateno PLC

International public company
10 Buckingham St., London,  WC2N 6DF, United Kingdom
()44 020 7004 2800, 44 020 7004 2801 fax, http://www.concateno.com

Primary SIC: In Vitro & In Vivo Diagnostic Agents, Primary NAICS: In-Vitro Diagnostic Substance Manufacturing
Description: Manufacturing: The development, manufacture and sale of medical diagnostic tests and services, predominantly those used for the detection of alcohol and drugs of abuse.

View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!

Concateno PLC, News and Information

FRAMLINGTON AIM VCT 2 PLC - Half-yearly Report.
PR Newswire UK Disclose; 10/29/2009; 6350 words; Framlington AIM VCT 2 PLC Interim report for the six months ended 31 August 2009 Overview of...Company has benefited from the takeover of the diagnostic company, Concateno, at a profit, and awaits the conclusion of the corporate acquisition...

Inverness Medical Innovations Announces Third Quarter 2009 Results.
PR Newswire; 10/27/2009; 5321 words; ...connection with the acquisition of Concateno plc, a $1.9 million compensation...connection with the acquisition of Concateno plc, a $0.3 million loss recorded...established in connection with the Concateno plc acquisition. GAAP results for...

Reportlinker Adds World Markets for Point of Care Diagnostics 2009-13 Report.
PR Newswire; 9/24/2009; 3030 words; ...Alere Medical Inc -- ARKRAY -- Axis-Shield plc -- Bayer Diabetes Care -- Beckman Coulter Inc...Chempaq A/S -- Cholestech Corporation -- Concateno Plc / Cozart Plc -- Crescent Diagnostics Ltd. -- DexCom, Inc...

S&P rates Inverness Medical Innovations' USD 100m notes at B-.
ADP Debt News; 9/23/2009; 547 words; ...health of its employees and covered lives. The transaction follows the recent USD 170 million acquisition of British Concateno plc, a provider of drugs of abuse testing. Both deals expand Inverness' product and service offerings. The B+ corporate...

UBS Investment Bank Strengthens Healthcare Banking Team by Hiring Four Managing Directors.
Business Wire; 9/16/2009; 1517 words; ...Initial Public Offering, the first U.S. biopharmaceutical IPO in the last 22 months; Exclusive Financial Advisor to Concateno Plc on its $240 million sale to Inverness Medical Innovations, Inc.; Joint Bookrunning Manager on Merck & Co...

Why Purchase This Company Profile?

  • Sales prospecting
  • Competitive analysis
  • Vendor & supplier evaluation
  • Customer evaluation and analysis
  • Strategic planning

Need More Information?

Start a new search

Tell Us What You Think

Take our short survey to tell us what would make Goliath more valuable to you.

Add Your Company Information to Goliath
If your company does not appear in Goliath, click here to add it.

Update Your Company Information
If your company information has changed or is not correct,
click here to let us know.